Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis
Endocrinology · 26.07.2024 · 165 (9)
DOI: 10.1210/endocr/bqae090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 24.07.2024. Verfasst von Nadejda Bozadjieva-Kramer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Hemochromatosis, Liraglutide, Iron, Mice, Knockout. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, BLRD VA, NIH HHS.
Abstract (Originalsprache)
Classic hereditary hemochromatosis (HH) is an autosomal recessive iron-overload disorder resulting from loss-of-function mutations of the HFE gene. Patients with HH exhibit excessive hepatic iron accumulation that predisposes these patients to liver disease, including the risk for developing liver cancer. Chronic iron overload also poses a risk for the development of metabolic disorders such as obesity, type 2 diabetes, and insulin resistance. We hypothesized that liraglutide, GLP1 receptor agonist, alters iron metabolism while also reducing body weight and glucose tolerance in a mouse model of HH (global HFE knockout, HFE KO) and diet-induced obesity and glucose intolerance. The total body HFE KO and wild-type control mice were fed high-fat diet for 8 weeks. Mice were subdivided into liraglutide and vehicle-treated groups and received daily subcutaneous administration of the respective treatment once daily for 18 weeks. Liraglutide improved glucose tolerance and hepatic lipid markers and reduced body weight in a mouse model of HH, the HFE KO mouse, similar to wild-type controls. Importantly, our data show that liraglutide alters iron metabolism in HFE KO mice, leading to decreased circulating and stored iron levels in HFE KO mice. These observations highlight the potential that GLP1 receptor agonist could be used to reduce iron overload in addition to reducing body weight and improving glucose regulation in HH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- Veterans Affairs Ann Arbor Healthcare System, Research Service, Ann Arbor, MI 48105, USA.
- Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
- Novo Nordisk Inc., Copenhagen, Denmark.
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Nadejda Bozadjieva-Kramer, Randy J Seeley
Förderung
- NIDDK NIH HHS
- BLRD VA
- NIH HHS
- VA
- NIH
- Department of Veterans Affairs
Zitieren
APA
Bozadjieva-Kramer, N., Shin, J. H., Blok, N. B., Jain, C., Das, N. K., Polex-Wolf, J., Knudsen, L. B., Shah, Y. M., & Seeley, R. J. (2024). Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis. Endocrinology, 165(9). https://doi.org/10.1210/endocr/bqae090
Vancouver
Bozadjieva-Kramer N, Shin JH, Blok NB, Jain C, Das NK, Polex-Wolf J, et al. Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis. Endocrinology. 2024;165(9). doi:10.1210/endocr/bqae090
BibTeX
@article{BozadjievaKramer2024,
author = {Bozadjieva-Kramer, Nadejda and Shin, Jae Hoon and Blok, Neil B and Jain, Chesta and Das, Nupur K and Polex-Wolf, Joseph and Knudsen, Lotte Bjerre and Shah, Yatrik M and Seeley, Randy J},
title = {Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis},
journal = {Endocrinology},
year = {2024},
volume = {165},
number = {9},
doi = {10.1210/endocr/bqae090}
}
EUVIMED